These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 31492813)
1. Regulation of GSK3 cellular location by FRAT modulates mTORC1-dependent cell growth and sensitivity to rapamycin. He L; Fei DL; Nagiec MJ; Mutvei AP; Lamprakis A; Kim BY; Blenis J Proc Natl Acad Sci U S A; 2019 Sep; 116(39):19523-19529. PubMed ID: 31492813 [TBL] [Abstract][Full Text] [Related]
2. GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth. Koo J; Wang X; Owonikoko TK; Ramalingam SS; Khuri FR; Sun SY Oncotarget; 2015 Apr; 6(11):8974-87. PubMed ID: 25797247 [TBL] [Abstract][Full Text] [Related]
3. mTORC1 Promotes Metabolic Reprogramming by the Suppression of GSK3-Dependent Foxk1 Phosphorylation. He L; Gomes AP; Wang X; Yoon SO; Lee G; Nagiec MJ; Cho S; Chavez A; Islam T; Yu Y; Asara JM; Kim BY; Blenis J Mol Cell; 2018 Jun; 70(5):949-960.e4. PubMed ID: 29861159 [TBL] [Abstract][Full Text] [Related]
4. Nuclear-cytoplasmic shuttling protein PP2A Nakatsumi H; Oka T; Higa T; Shirane M; Nakayama KI Genes Cells; 2018 Jul; 23(7):599-605. PubMed ID: 29845697 [TBL] [Abstract][Full Text] [Related]
5. Frat is a phosphatidylinositol 3-kinase/Akt-regulated determinant of glycogen synthase kinase 3β subcellular localization in pluripotent cells. Bechard M; Trost R; Singh AM; Dalton S Mol Cell Biol; 2012 Jan; 32(2):288-96. PubMed ID: 22064483 [TBL] [Abstract][Full Text] [Related]
7. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition. Ito H; Ichiyanagi O; Naito S; Bilim VN; Tomita Y; Kato T; Nagaoka A; Tsuchiya N BMC Cancer; 2016 Jul; 16():393. PubMed ID: 27387559 [TBL] [Abstract][Full Text] [Related]
8. Phosphorylation of PBX2, a novel downstream target of mTORC1, is determined by GSK3 and PP1. Wada R; Fujinuma S; Nakatsumi H; Matsumoto M; Nakayama KI J Biochem; 2023 Feb; 173(2):129-138. PubMed ID: 36477205 [TBL] [Abstract][Full Text] [Related]
9. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility. Gulati N; Karsy M; Albert L; Murali R; Jhanwar-Uniyal M Int J Oncol; 2009 Oct; 35(4):731-40. PubMed ID: 19724909 [TBL] [Abstract][Full Text] [Related]
10. Rapamycin attenuates BAFF-extended proliferation and survival via disruption of mTORC1/2 signaling in normal and neoplastic B-lymphoid cells. Zeng Q; Qin S; Zhang H; Liu B; Qin J; Wang X; Zhang R; Liu C; Dong X; Zhang S; Huang S; Chen L J Cell Physiol; 2018 Jan; 233(1):516-529. PubMed ID: 28300280 [TBL] [Abstract][Full Text] [Related]
11. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin. Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676 [TBL] [Abstract][Full Text] [Related]
12. Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1. Rosner M; Hengstschläger M Hum Mol Genet; 2008 Oct; 17(19):2934-48. PubMed ID: 18614546 [TBL] [Abstract][Full Text] [Related]
13. The regulation of glycogen synthase kinase-3 nuclear export by Frat/GBP. Franca-Koh J; Yeo M; Fraser E; Young N; Dale TC J Biol Chem; 2002 Nov; 277(46):43844-8. PubMed ID: 12223487 [TBL] [Abstract][Full Text] [Related]
14. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells. Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608 [TBL] [Abstract][Full Text] [Related]
16. AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis. Mi W; Ye Q; Liu S; She QB Oncotarget; 2015 Jun; 6(16):13962-77. PubMed ID: 25961827 [TBL] [Abstract][Full Text] [Related]
17. The mTOR pathway controls cell proliferation by regulating the FoxO3a transcription factor via SGK1 kinase. Mori S; Nada S; Kimura H; Tajima S; Takahashi Y; Kitamura A; Oneyama C; Okada M PLoS One; 2014; 9(2):e88891. PubMed ID: 24558442 [TBL] [Abstract][Full Text] [Related]
18. Phosphorylation of the novel mTOR substrate Unkempt regulates cellular morphogenesis. Baskaran P; Mihaylov SR; Vinsland E; Shah K; Granat L; Ultanir SK; Tee AR; Murn J; Bateman JM J Biol Chem; 2023 Jan; 299(1):102788. PubMed ID: 36509146 [TBL] [Abstract][Full Text] [Related]
19. Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy. Choo AY; Blenis J Cell Cycle; 2009 Feb; 8(4):567-72. PubMed ID: 19197153 [TBL] [Abstract][Full Text] [Related]
20. Endothelial replicative senescence delayed by the inhibition of MTORC1 signaling involves MicroRNA-107. Khor ES; Wong PF Int J Biochem Cell Biol; 2018 Aug; 101():64-73. PubMed ID: 29857052 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]